Taltz® (Ixekizumab)

Para consultar la información para prescribir completa de Taltz® (Ixekizumab) de clic en el siguiente enlace: Información para prescribir

La información es proporcionada en respuesta a su solicitud, y puede contener datos relacionados a dosis, usos, formulaciones y poblaciones diferentes a la Información para Prescribir del producto. Consulte la Información para Prescribir en la liga que aparece arriba.

Can ixekizumab be used in combination with methotrexate for the treatment of psoriasis?

The safety and efficacy of combination therapy with ixekizumab and methotrexate in patients with moderate-to-severe plaque psoriasis have not been evaluated by Lilly.

MX_cFAQ_IXE329_ADDITION_METHOTREXATE_PsO
MX_cFAQ_IXE329_ADDITION_METHOTREXATE_PsO
es-MX

Systemic Psoriasis Therapies Clinical Trial Exclusion Criteria

This medical response may not completely match the information in the current local labeling for IXEKIZUMAB. Please see local labeling for approved label information.

During the pivotal ixekizumab UNCOVER clinical trials, treatment with concomitant systemic psoriasis therapies, including methotrexate, was not permitted. Patients were excluded if they had received methotrexate within 4 weeks of the baseline visit.1

The rationales for excluding concomitant medications were the potential safety impact on patients enrolled in the study and the potential to confound the results of the study. 

Reference

1Gordon KB, Blauvelt A, Papp KA, et al; UNCOVER-1, UNCOVER-2, and UNCOVER-3 Study Groups. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345-356. http://dx.doi.org/10.1056/NEJMoa1512711

Fecha de la última revisión: 2021 M07 26


Contáctenos para saber más de la información Médica de Lilly

Contacto vía correo electrónico

Correo electrónico: infomed@lilly.com

Envíe su consulta

Escriba su consulta